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Abstract
Coronavirus disease 2019 (COVID-19) pandemic represents a scientific and social crisis. One of the main unmet needs for coronavirus disease 2019 is 
its unpredictable clinical course, which can rapidly change in an irreversible outcome. COVID-19 patients can be classified into mild, moderate, and 
severe. Several haematological parameters, such as platelets, white blood cell total count, lymphocytes, neutrophils, (together with neutrophil-
lymphocyte and platelet-lymphocyte ratio), and haemoglobin were described to be associated with COVID-19 infection and severity. The purpose 
of these review is to describe the current state of the art about complete blood count alterations during COVID-19 infection, and to summarize the 
crucial role of some haematological parameters during the course of the disease. Decreased platelet, lymphocyte, haemoglobin, eosinophil, and 
basophil count, increased neutrophil count and neutrophil-lymphocyte and platelet-lymphocyte ratio have been associated with COVID-19 infection 
and a worse clinical outcome. Our study adds some novelty about the identification of effective biomarkers of progressive disease, and might be 
helpful for diagnosis, prevention of complications, and effective therapy.
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Introduction
In December 2019, coronavirus disease 2019 (COV-
ID-19) was firstly reported in Wuhan, China. The 
pathogenic agent was determined to be a novel 
b-coronavirus, which is currently named severe 
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) (1). Patients experience a spectrum of dis-
ease from a mild illness, through varying severity 
of pneumonia all the way to acute respiratory dis-
tress syndrome (ARDS) and sepsis with multi-or-
gan failure and death. The majority of patients de-
velop pneumonia, which can proceed in up to 20-
30% of cases to respiratory failure requiring intu-
bation and ventilatory support (2). Because of the 
rapid spread of the COVID-19 pandemic, affected 
countries have taken a heterogeneous and evolv-
ing approach to the diagnosis of infection in pa-
tients, and continue to have different and, in some 
cases, evolving strategies to determine what seg-
ments of the population should be tested. Cur-
rently, the gold standard for the diagnosis of COV-
ID‐19 patients is the detection of SARS‐CoV‐2 nu-
cleic acid by real‐time reverse transcription poly-
merase chain reaction (RT-PCR) in respiratory 
specimens (oro- and nasopharyngeal swabs, spu-
ta, nasal aspirates and washes, bronchoalveolar 
lavage and lung tissue specimens collected at au-
topsy) (3). Based on studies conducted in China 
and elsewhere, the clinical haematology laborato-
ry plays an important role by providing the clinical 
team a number of useful prognostic markers and 
might be an important partner in the triage and 
management of affected patients. Some laborato-
ry abnormalities include the decreased white 
blood cell and lymphocyte count, neutrophilia, 
thrombocytopenia, increased C‐reactive protein 
(CRP), erythrocyte sedimentation rate (ESR), and 
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abnormal procalcitonin (PCT) in most patients (4). 
In particular, the blood count of patients with 
COVID-19 infection at diagnosis shows alterations 
that correlate with the stage and severity of the 
disease (5).
Laboratory blood tests have not been assessed 
with regard to their sensitivity or specificity for the 
diagnosis of COVID-19, nor their value as prognos-
tic indicators. This literature review summarizes 
the blood cell count variations and their clinical 
significance in COVID-19 patients, having the pur-
pose to gain an understanding of the existing data 
about haematological alterations occurring in 
COVID-19 infection, and debating particular prog-
nostic markers which may be useful to stratify pa-
tients at the early diagnosis and eventually pro-
vide prompt treatment.
Literature search
A literature search was performed using the Pub-
Med and Google Scholar databases to identify 
studies on haematological findings of COVID-19 
up to April 2021. The keywords used in the search 
were as follows: SARS-CoV-2, COVID-19, blood 
count, laboratory findings, and haematology. The 
initial selection was based on the article title and 
abstract, following which the full-text article was 
read. Inclusion criteria were any study or article 
that included information about laboratory altera-
tions in SARS-CoV-2. All types of studies and coun-
tries of origin were eligible for inclusion. We ex-
cluded articles that exclusively reported data on 
coagulative parameters, or that did not relate to 
the clinical aspects of interest, and that were not 
written in the English language. The findings from 
primary research articles, reviews, case reports, 
and case series were summarized and discussed 
narratively. Our search retrieved 446 records, of 
which 253 were excluded via title and abstract 
screening. A total of 193 full articles were assessed 
for eligibility. Of these, 120 papers relating to 
blood cells and SARS-CoV-2 were identified, from 
which data were extracted and synthesized. Arti-
cles relevant to the topic were included in the ref-
erence lists, after removing duplicates.
Platelets
Platelet (PLT) count is an important parameter in-
cluded in numerous classification systems that 
evaluate disease severity, such as in multiorgan 
dysfunction syndrome. In COVID-19 infection, the 
presence of thrombocytopenia correlates with the 
severity of the disease and indicates the presence 
of a consumption coagulopathy. Similar to pub-
lished data on severe acute respiratory syndrome 
and Middle East respiratory syndrome infection, it 
is found in approximately 60% of severe patients 
(6). Lippi et al. correlated a low PLT count with 
higher mortality and more severe COVID-19 illness 
(7). Platelet number was found to be lower in pa-
tients with either more severe illness or poor out-
comes and even lower in non-survivors. An inter-
esting point of the subgroup analysis is that 
thrombocytopenia may not be significantly relat-
ed to intensive care unit (ICU) admission. This as-
pect could be explained considering that throm-
bocytopenia tends to reach a significant level in 
the late clinical stage of COVID-19 (8).
The mechanism by which the coronavirus inter-
feres with the haematopoietic system is still un-
clear. Three mechanisms of a cascade can be as-
sumed to explain thrombocytopenia in SARS-
CoV-2 infections: 1) direct infection of bone mar-
row cells by the virus with inhibition of PLT synthe-
sis; 2) destruction of PLTs by the immune system; 
3) aggregation of PLTs in the lungs with the forma-
tion of microthrombi and further consumption of 
PLTs.
Viruses can interact with megakaryocytes and re-
duce PLT synthesis (9). It has been assumed that 
the SARS-CoV-2 inhibits bone marrow haemat-
opoiesis through specific receptors to depress the 
primary formation of PLTs and resulting thrombo-
cytopenia (10). Viral infection and inflammation re-
sult in pulmonary capillary damage. Damaged 
lung tissues and pulmonary endothelial cells may 
cause a process of megakaryocyte rupture and in-
creased PLT consumption (11). Also, SARS-CoV-2 
can boost autoantibodies and immune complex-
es, resulting in the specific destruction of PLTs by 
the immune system (12). While PLTs contribute to 
the basal barrier integrity of the alveolar capillar-
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ies, they may also contribute to lung injury in a va-
riety of pulmonary disorders and syndromes (13). 
PLT-leukocyte aggregates and PLT-endothelial in-
teractions appear to play a role in the pathogene-
sis of acute lung injury (14). In Covid-19 infection, 
the damage of the lung tissues and lung endothe-
lial cells can cause PLT aggregations with the for-
mation of micro thrombi and further consumption 
of PLTs (15). In fact, most patients with thrombocy-
topenia have high concentrations of D-dimers 
with alteration of the coagulation parameters that 
confirm the hypothesis of triggering intravascular 
coagulation (16).
The PLT count associated with the hypoxemia val-
ue has also been described as a predictive model 
of the severity of the disease, with an accuracy of 
96% (17). Conversely, only a small fraction of pa-
tients have thrombocytosis (18). COVID-19 patients 
were found to have significantly larger mean 
platelet volume (MPV) than critically ill non-COV-
ID-19 patients matched for PLT count (11.6 vs 10.5 
fL, P = 0.013). Moreover, there was a significant 
trend of elevated immature platelet fraction (IPF) 
in COVID-19 patients. COVID-19 positivity was 
highly predictive of an absolute IPF of 7.5 x109/L or 
higher; also, COVID-19-positive patients had rela-
tive IPF ≥ 8% at PLT counts up to 251 x109/L. In 
contrast, in the non-COVID-19 patients, a relative 
IPF of ≥ 8% was restricted to those with PLT counts 
less than 70 x109/L (19). These findings suggest 
that COVID-19 is associated with the increased 
production of large immature PLTs, as megakaryo-
cytes respond to increased PLT consumption.
White blood cells
Lymphocytes
The best recognized haematological abnormality 
in patients affected by COVID-19 infection is lym-
phopenia, which is seen in up to 85% of severe 
cases with the severity of lymphopenia linked to 
outcome (20). The presence of lymphopenia (de-
fined by an absolute number of lymphocytes < 1.0 
x109/L) is reported in most of the published series 
and is commonly considered to be a deficient im-
munological response to viral infection (21).
Since the SARS-CoV-2 was identified, this novel vi-
rus began to be compared to influenza. Of respira-
tory infections, influenza is the most well studied 
viral infection and is commonly reported as the 
cause of epidemics. The lymphocyte count of the 
severe COVID-19 group was found to be signifi-
cantly lower than in the common COVID-19 and in-
fluenza groups (P < 0.001 and P = 0.012). Common 
cases of Covid-19 infection were defined as those 
who had a fever, respiratory tract symptoms, and 
pneumonia on imaging. Severe cases were those 
who had one of the following three clinical mani-
festations: (a) shortness of breath with a respirato-
ry rate greater than 30 breaths/min, (b) mean oxy-
gen saturation ≤ 93% in the resting state, and (c) 
partial pressure of arterial oxygen/oxygen concen-
tration ≤ 300 mmHg. Severe cases also included 
the progress of lesions by more than 50% within 
24 to 48 hours, as detected by pulmonary imag-
ing. All influenza cases were confirmed by RT‐PCR 
assay of nasal and pharyngeal swab specimens. 
Lymphocytes percentage rate of influenza and se-
vere COVID‐19 groups were significantly lower 
than in the common COVID‐19 group (P < 0.001) 
(22). In a cohort of 120 COVID-19 patients, 100 in-
fluenza patients, and 61 healthy controls, lower 
lymphocytes were found in COVID-19 and influen-
za groups compared to healthy controls (23). How-
ever, distinct subpopulations of CD8+ T cells might 
be involved in COVID-19 and influenza. When ana-
lysing disease-specific transcriptional signatures in 
CD8+ T cells, the authors found that biological 
pathways for responses to interferon (IFN)-I and -II 
were more associated with the influenza-specific 
cellular cluster, whereas pathways for the response 
to tumour necrosis factor (TNF) or interleukin-1β 
(IL-1β) were more prominent in COVID-19-specific 
clusters (24). In summary, COVID‐19 and influenza 
can cause different changes in peripheral blood 
parameters, which should be considered in the 
early stages of COVID‐19 and influenza.
It is well known that alteration in total lymphocyte 
numbers and the subsets varies with different vi-
rus types, indicating a potential association be-
tween lymphocyte subset alteration and viral 
pathogenic mechanisms (25). Lymphopenia might 
be caused by virus attachment or indirectly by im-
Biochem Med (Zagreb) 2021;31(3):030501  https://doi.org/10.11613/BM.2021.030501 
4
Palladino M. Blood count and COVID-19 
mune injuries from inflammatory mediators. 
Moreover, exudation of circulating lymphocytes 
into inflammatory lung tissues might also lead to 
lymphopenia. The reduction of lymphocyte sub-
set count in COVID-19 patients was investigated 
across 20 peer-reviewed studies for reporting lym-
phocyte subset counts and COVID-19 disease se-
verity. CD4+ T cell, CD8+ T cell, B cell, Natural killer 
(NK) cell, and total lymphocyte cell counts all 
showed a statistically significant reduction in pa-
tients with severe/critical COVID-19 disease com-
pared to mild/moderate disease (26). The results 
remained consistent despite the differences in the 
definition of disease severity across the studies 
(27-29). Counts of total, CD4+, or CD8+ T cells low-
er than 800, 400, or 300/µL, respectively, were 
negatively correlated with the patient outcome; 
the counts of the total, CD4+, and CD8+ T cells, im-
portantly, were significantly lower in ICU patients 
than non-ICU cases. Further, an age-dependent 
reduction of T cell numbers was observed, with 
the lowest T cells numbers found in patients ≥ 60 
years old, thus suggesting a potential cause for in-
creased susceptibility in elderly patients (27). No 
significant difference was observed in CD4+/CD8+ 
ratio and NK cells in severe cases compared with 
mild illness (28), (Table 1). Total lymphocytes, 
CD4+, and CD8+ T cells were also found to inverse-
ly correlate with inflammatory indicators as ESR 
and CRP, while CD4+/CD8+ ratio was directly cor-
related with ESR and CRP (28). However, the ex-
pression of cell surface and intracellular molecules 
is not detectable by routine automated cell coun-
ter but needs to be analysed by flow cytometry.
Along with the severity of COVID-19 disease, a pro-
gressive T cell exhaustion, mediated by the ex-
pression of some immune-inhibitory molecules, 
has been evidenced during the course of infection 
(30). It is well known that persistent stimulation by 
the virus may induce T cell exhaustion, leading to 
loss of cytokine production and cellular dysfunc-
tion (31). On the other hand, efficacious therapy 
with chloroquine was accompanied by an in-
creased number of T cells and NK cells. Therefore, 
it might be hypothesized that in COVID-19 patients 
with severe pulmonary inflammation, SARS-CoV-2 
correlates with functional exhaustion of cytotoxic 
lymphocytes at the early stage, which may result 
in disease (29). A low T cells count, an increase in 
naïve helper T cells, and a decrease in memory 
helper T cells were found in patients severely af-
fected by COVID‐19 (32). Moreover, a lower level of 
regulatory T cells has been found in severe cases 
(20). Reconstitution of lymphocytes may be an im-
portant factor for recovery (33). Low lymphocyte 
count might be used by clinicians in risk stratifica-
tion to predict severe and fatal COVID-19 in hospi-
talized patient.








































(< 0.01) n.a. n.a. n.a.
























n.a. – not available. NK – Natural killer cell. COVID-19 – coronavirus disease 2019.
Table 1. Findings for CD4+, CD8+, CD4+/CD8+ ratio, NK cells variations in severe/critical COVID-19 disease compared to mild/moder-
ate disease
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Neutrophils
Neutrophilia, except for patients with bacterial in-
fections or superinfections, correlates with hyper-
inflammatory state and cytokine storm, an inte-
gral part of the pathogenic mechanism of COV-
ID-19. Neutrophils are involved in many viral res-
piratory diseases associated with ARDS (34). A mi-
nority of patients present leucocytosis, supported 
by neutrophilia: this finding seems to correlate 
with a more severe course (35). As COVID-19 pro-
gresses, the number of circulating neutrophils 
gradually increases; thus, neutrophilia has been 
identified as a marker of severe respiratory disease 
and a poor outcome (36). Leukocytes and neutro-
phils were significantly higher in severe than in 
non-severe COVID-19 infected patients. Further, 
along with COVID-19 disease progression, both 
leukocyte and neutrophil counts increased in the 
severe groups (37).
In peripheral blood smear, morphological altera-
tions in circulating neutrophils, such as the reduc-
tion of nuclear lobularity and the presence of 
heavy cytoplasmic granulations, have been de-
scribed (38). These morphological changes were 
transient and reversible preceding the appearance 
of the large reactive atypical lymphocytes, charac-
teristic of viral infections (39).
The increase of neutrophils has been reported not 
only in the bloodstream but also in the lung tissue 
(40). The increased infiltration of immature and/or 
dysfunctional neutrophil contributes to the abnor-
mal lungs’ immune response in severe patients. 
Similar to other viral infections, SARS-CoV-2 infec-
tion promotes neutrophil extracellular traps re-
lease, which can contribute to tissue damage. Ab-
errant activation of neutrophils might exacerbate 
host response in COVID-19. Lung autopsies re-
vealed the presence of neutrophils in lung capillar-
ies and their extravasation into alveolar space (41). 
Neutrophils have a crucial role as drivers of hyper-
inflammation associated with COVID-19 disease 
via enhanced degranulation and cytokine produc-
tion (42). On the day of hospital admission, the me-
dian neutrophil count in severe COVID-19 patients 
was found higher than in the moderate and mild 
groups. Further, an increase in neutrophil count 
from day 7 to day 9 after symptom onset was evi-
denced. Given the relationship between neutro-
philia and poor outcomes, it has been proposed 
that the change in neutrophil counts in peripheral 
blood or tissues might be strictly associated with 
lung damage in COVID-19 patients (43). Confirma-
tion of these findings might lead to targeting neu-
trophils and their recruitment mediators to reduce 
the severity of COVID-19.
Neutrophil-lymphocyte and 
platelet-lymphocyte ratio
The neutrophil-lymphocyte ratio (NLR: absolute 
neutrophil count/absolute lymphocyte count) and 
platelet-lymphocyte ratio (PLR: absolute platelet 
count/absolute lymphocyte count) have been re-
ported to be useful in the diagnosis, follow-up, 
and survey of various systemic inflammatory pro-
cesses, such as cholangiocarcinoma, ischemic 
heart disease, acute pancreatitis, and as a prog-
nostic marker of malignant tumours (44-47).
Neutrophil-lymphocyte ratio is elevated in the 
bloodstream of COVID-19 infected patients; Zhang 
et al. reported that NLR combined with IgG might 
be a better predictor than neutrophil count alone 
in predicting the severity of COVID-19 (48). Levels 
of NLR and PLR correlate with COVID-19 disease se-
verity. Patients with severe disease had higher NLR 
and PLR values compared to non-severe diseases 
(49). Neutrophil-lymphocyte ratio and PLR have 
been considered independent factors associated 
with COVID-19 progression; however, the mecha-
nisms behind this are not understood (50). At the 
early stage of COVID-19, the total number of leuko-
cytes in peripheral blood is normal or decreases, 
while the lymphocyte count decreases (51). The ini-
tial and peak value of NLR in deceased patients 
were higher than in survivors (P < 0.001) (52). The 
increase of NLR means the progressive increase of 
neutrophils, and/or the decrease of lymphocytes. 
The increase of neutrophils often suggests an un-
derlying bacterial infection, while the decrease of 
lymphocytes means a compromised system (53). 
Those suggest that it is necessary to pay attention 
to the COVID-19 patients with increased NLR (52). 
Worse outcomes were noted in patients presenting 
with a peak in the platelet count during the disease 
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course, and the PLR at the time of platelet peak was 
identified as an independent prognostic factor for 
prolonged hospitalization (54). A case report de-
scribes NLR and PLR fluctuation during the pro-
gression of COVID-19 disease. From the admission, 
white blood cells, neutrophils, platelets, and the 
NLR gradually increased and reached a peak on the 
14th day, the PLR reached a peak on the 9th day, 
while the number of lymphocytes did not reach 
the maximum value, but it showed only an upward 
trend. The NLR and the PLR gradually returned to 
normal after the patient’s improvement on the 14th 
day (55). In COVID-19 patients, the levels of new se-
rological biomarkers, including NLR and PLR, were 
elevated in the severe disease group compared to 
those in mild to moderate patients (56). In a differ-
ent study, no statistically significant difference was 
observed between COVID-19 negative and positive 
patients, respectively, regarding lymphocyte and 
PLR values (P = 0.081), while a statistically signifi-
cant difference (P < 0.001) was found between the 
test groups regarding NLR values (57).
In COVID-19 patients, increased ferritin and PLR 
were found to be independent predictors of the 
disease severity (58). SARS-CoV-2-triggered hyper-
inflammation seems to increase PLR, which pro-
motes severe prognosis. Studies suggested that 
PLR was linked to inflammation and could predict 
mortality among haemodialysis patients (59). Neu-
trophil-lymphocyte ratio and PLR are easily ob-
tained from a serum complete blood count with a 
differential profile. They serve as a function of rela-
tive neutrophilia, thrombocytosis, and lymphope-
nia. While many inflammatory markers like CRP, 
ESR, lactate dehydrogenase, ferritin, and PCT are 
frequently measured in COVID-19 patients, NLR 
and PLR can be easily calculated using the differen-
tial count and are cost-effective especially for many 
third world countries. Monitoring the predictors of 
severity may assist clinicians to identify and follow-
up patients with a higher risk for progression.
Monocytes
Monocytes constitute about 5-9% of the total pe-
ripheral leukocytes, remain in the circulation for 1-2 
days, following which these cells may differentiate 
to tissue-resident macrophages (60). SARS-CoV2 in-
fects CD14+ monocytes through angiotensin-con-
verting enzyme (ACE2), but viral replication in 
these cells is usually low or undetectable (61,62). 
Anyway, the SARS-CoV-2-infected monocytes can 
produce large amounts of inflammatory mediators 
that support COVID-19-associated cytokine storm 
(63). Wen et al. revealed a predominant subset of 
CD14++IL1β+ monocytes in patients in the early re-
covery stage of COVID-19 (64). Zhang D et al. did 
not detect significant differences in the absolute 
number of monocytes between patients with COV-
ID-19 and normal healthy individuals but identified 
an increased proportion of activated monocytes/
macrophages in patients with COVID-19, and signif-
icant morphological and functional differences, 
which are more pronounced in patients requiring 
prolonged hospitalization and ICU admission. In 
particular, the numbers of circulating classical 
monocytes (CD14++CD16−) decrease, but the 
numbers of intermediate (CD14++CD16+) and non-
classical (CD14+CD16++) monocytes increase in 
COVID-19 patients. Moreover, patients with COV-
ID-19 have larger than normal monocytes, easily 
identified on forward scatter (FSC) analysis by rou-
tine flow cytometry, with the presence of a distinct 
population of monocytes with high FSC. These 
FSC-high monocytes are CD11b+, CD14+, CD16+, 
CD68+, CD80+, CD163+, CD206+ and secrete IL-6, 
IL-10, and TNF-alpha, consistent with an inflamma-
tory phenotype. In contrast, patients with a high 
proportion of normal monocytes have a better 
prognosis with earlier recovery and discharge from 
the hospital. These findings appear to be relatively 
specific for COVID-19 as we have not seen a similar 
pattern in patients with other viral illnesses, such as 
H1N1 influenza and human immunodeficiency vi-
rus (HIV) (61). A significant expansion of popula-
tions of CD14+CD16+ monocytes producing IL-6 
was observed in the peripheral blood of patients 
with COVID-19 in ICU compared with those pa-
tients who did not require ICU hospitalization. 
Moreover, monocytes from COVID-19 patients 
were found to be able to secrete granulocyte-mac-
rophage colony-stimulating factor  (GM-CSF) (65). 
As the monocyte is the pathogenic GM-CSF re-
sponsive cell that requires GM-CSF to promote tis-
sue damage in both mouse and human, it has been 
suggested that the increasing number of GM-CSF+ 
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monocytes and IL-6+ monocytes in the peripheral 
blood is responsible for inflammatory cytokine 
storms occurring in COVID-19 infection (65,66). 
SARS-CoV-2 infection of monocytes, which acts as 
antigen presenting cells, directly impairs the anti-
viral adaptive immune responses. Thus, interfering 
with monocytes infection and subsequent activa-
tion of cytokine production and cytokine-mediat-
ed signalling pathways can also attenuate systemic 
hyperinflammation.
Eosinophils
The role of eosinophils in the coronavirus-19 dis-
ease is unknown. Physiologically, tissue-resident 
eosinophils are mainly represented in the gastro-
intestinal tract and in the lung, where they have 
regulatory functions in protective immunity, and 
organ growth and metabolism (67). In a popula-
tion of 140 patients infected with SARS-CoV-2 in 
Wuhan, 53% of the patients had eosinopenia at 
admission (68). Mu et al. evidenced a significant 
eosinopenia in 72/95 SARS-CoV-2 patients (P < 
0.01). The absolute eosinophil count was 0.01 
x10⁹/L and the eosinophil percentage was 0.3%. 
Moreover, eosinophil blood count progressively 
returned to normal together with clinical condi-
tions improvement, while continued to decline for 
patients without clinical improvement (69). In a 
retrospective analysis by Tan et al., decreased eo-
sinophils were detected in 33 out of 40 patients 
with COVID‐19 on admission, while eosinophils 
were inversely related to the severity of the dis-
ease, according to the Spearman’s correlation co-
efficient (rs = -0.462; P = 0 .003). Furthermore, the 
patients’ peripheral blood eosinophils returned to 
normal values before the discharge, suggesting a 
putative role of eosinophils in predicting the prog-
nosis of the patient (70).
Eosinopenia as a response to infection was first 
described in Zappert (71). The pathophysiology for 
eosinopenia in COVID-19 remains unclear but is 
likely multifactorial and related to the migration of 
eosinophils to the inflammatory site, inhibition of 
eosinophil mobilization from the bone marrow, 
blockade of eosinophilopoiesis, reduced expres-
sion of chemokine receptors/adhesion molecules, 
and/or direct eosinophil apoptosis induced by 
IFN-I released during the acute phase of inflamma-
tion (72,73).
Basophils
In-vivo, basophils leave the circulation and migrate 
to inflammatory sites during allergic inflammation 
and infection, enhancing immunological memory 
responses by binding antigens on their surface 
(74). Secretion of IgM or a class switch to IgG or IgA 
by B cells is enhanced by activated basophils (75).
Rodriguez et al. demonstrated that basophils are 
depleted during acute and severe COVID-19, thus 
suggesting that the degree of basophil depletion 
may influence the efficacy of IgG responses to 
SARS-CoV-2 (76). Lower basophils were found in 
COVID-19 and influenza groups compared to 
healthy controls (77). Li et al. found that in the ear-
ly stages of the disease, basophils counts were 
lower in COVID-19 patients than in controls (78). It 
is known that both basophils and eosinophils can 
produce IL-4, which is an important cytokine to 
stimulate the proliferation of activated B and T 
cells (79). Therefore, the decrease of basophil and 
eosinophil counts in COVID-19 patients may fur-
ther explain the decrease of lymphocyte count. In 
a cohort of 452 patients affected by severe COV-
ID-19 disease, higher leukocyte, and neutrophil 
counts and a lower percentage of basophils were 
found (20). Interestingly, low basophil counts were 
associated with viral infections in immunocom-
promised patients (80). On the other hand, it has 
been demonstrated that several HIV proteins can 
interact with different surface receptors on human 
basophils; also, HIV-infected basophils were found 
in the peripheral blood of acquired immunodefi-
ciency syndrome patients (81,82). Based on these 
considerations, a mechanism of viral encapsula-
tion in basophils might be postulated as one pos-
sible explanation of low basophil count in patients 
affected by COVID-19 infection.
Red blood cells and haemoglobin
A significant impact of SARS-Co-V2-infection on 
red blood cell (RBC) structural membrane homeo-
stasis at the protein and lipid levels was demon-
strated. RBCs from COVID-19 patients had in-
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creased levels of glycolytic intermediates, accom-
panied by oxidation and fragmentation of mem-
brane proteins. Thus, COVID-19 impacts two criti-
cal mechanisms that finely tune red cell mem-
branes and haemoglobin oxygen affinity. RBCs 
from COVID-19 patients may be incapable of re-
sponding to environmental variations in haemo-
globin oxygen saturation when traveling from the 
lungs to the bloodstream and, as such, may have a 
compromised capacity to transport and deliver 
oxygen (83). COVID-19 patients show higher levels 
of nitric oxide (NO) inside RBC compared to non-
COVID-19 hypoxemic patients, but the 
mechanism(s) causing the accumulation of intra-
cellular NO in RBC of COVID-19 patients is still un-
clear (84). Autoimmune haemolytic anaemia 
(AIHA) was recently described in COVID-19 pa-
tients (85). Autoimmune haemolytic anaemia 
causes platelet cell death and RBCs can also mod-
ulate platelet activity through either chemical sig-
nalling or direct RBC-platelet interactions. Thus, 
evidence for haemolysis may account for the mi-
crovascular coagulation seen in COVID-19 patients. 
Berzuini et al. reported the observation that about 
half of patients with COVID-19 tested at their blood 
center had a positive direct antiglobulin test (DAT). 
However, eluates did not react with any test cells 
but did react with red cells from patients with 
COVID-19 that were DAT negative. This suggests 
that COVID-19 may modulate the red cell mem-
brane and present novel antigenic epitopes (86). 
Patients with COVID-19 present decreased haemo-
globin concentration and pathologically increased 
concentrations of ferritin. Wang et al. reported re-
duced haemoglobin concentration (< 110 g/L) in 
19% of the hospitalized patients (87); while Huang 
et al. reported reduction in haemoglobin concen-
trations in 38% of the study population admitted 
to the hospital (88). In this case, the higher inci-
dence of a low haemoglobin concentration in 
COVID-19 patients described by Huang might be 
explained by the difference in age structure be-
tween the populations from the two studies. In 
fact, Huang et al. reported data from a population 
aged 56 (26-88), while the study population de-
scribed by Wang et al. had a median age of 42 (33–
53). Haemoglobin concentration below 110 g/L 
was associated with disease progression (89). On 
the other hand, Cai et al. discovered no associa-
tions between haemoglobin concentration and 
risk of admission at ICU (90). Taneri et al. analysed 
data from 189 studies and 57,563 COVID-19 pa-
tients across all ages, founding a pooled mean 
haemoglobin concentration of 129.7 g/L, which 
decreased with older age and a higher proportion 
of comorbid illness and disease severity. They also 
found increased values of ferritin in most patients, 
mainly in males, the elderly, and individuals with 
hypertension (91). Based on data from 54 observa-
tional studies, including 24,262 COVID-19 patients, 
pooled mean ferritin concentration in COVID-19 
patients was 777.33 ng/mL Moreover, the mean 
difference in serum ferritin was higher in severe 
COVID-19 individuals compared to moderate cas-
es. A linear trend with ferritin concentrations be-
tween severe and moderate COVID-19 cases in-
creasing with advancing age was observed, while 
non-linear trends were observed between pa-
tients’ characteristics and ferritin concentration 
among survivors and non-survivors. Odds in hos-
pital death were higher among patients with ferri-
tin above 300 ng/mL compared to those with se-
rum ferritin ≤ 399 ng/mL (odds ratio 9.10 [(95% CI 
2.04 to 40.58, P = 0.004]). Concentrations of serum 
ferritin were elevated in non-survivors compared 
with survivors (562 ng/mL vs 492 ng/mL) through-
out the clinical course and were increased with 
disease deterioration (92). In another study, ferritin 
was significantly higher in severe cases (93). Both 
anaemia and hyperferritinemia, regardless of the 
underlying pathology, are associated with in-
creased mortality (94). Haemoglobin concentra-
tions were found lower with older age, a higher 
percentage of subjects with diabetes, hyperten-
sion, and overall comorbidities, and admitted to 
intensive care. Ferritin concentration increased 
with older age, increasing proportion of hyperten-
sive study participants, and increasing proportion 
of mortality. Compared to moderate cases, severe 
COVID-19 cases had lower haemoglobin and RBC 
and higher ferritin and red cell distribution width 
(RDW) (95).
Anaemia could be the result of a sideroblastic-like 
anaemia pattern arising from alterations in iron 
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metabolism, while increased ferritin could be in-
dicative of a strong inflammatory reaction in COV-
ID-19 or related to viral entry into the human body 
and its impact on iron metabolism. Functional iron 
deficiency was associated with significantly poorer 
clinical conditions and a longer hospital stay but 
was not linked to an increased risk of in-hospital 
death, ICU admission, or the need for mechanical 
ventilation. No significant relations were found be-
tween mortality rate and elevated ferritin concen-
trations. However, elevated ferritin concentrations 
were associated with longer hospital stays and in-
creased risk for ICU admission and the need for 
mechanical ventilation (96). In COVID-19 infection, 
inflammation is related to iron metabolism bio-
markers, and haemoglobin. Anaemic patients had 
significantly higher CRP, IL-6 and PCT levels. Ac-
cordingly, haemoglobin concentrations were only 
significantly correlated with CRP and tended to be 
related to IL-6, and PCT concentrations. In addi-
tion, patients with functional iron deficiency had 
significantly higher CRP, IL-6, and PCT concentra-
tions when compared to patients with absolute 
iron deficiency or no iron deficiency. Accordingly, 
ferritin positively correlated with CRP, IL-6, and PCT 
concentrations. Taken together, these data are in 
accordance with the association of altered iron ho-
meostasis with more advanced inflammation, the 
latter promoting lung injury and respiratory failure 
(97). Nonetheless, both anaemia and inflamma-
tion-induced alterations of iron homeostasis are 
important clinical predictors for risk stratification 
of SARS-CoV-2-infected patients.
Severe acute respiratory syndrome coronavirus 2 
was shown to interfere with haemoglobin at eryth-
rocyte and bone marrow level; the new SARS-CoV2 
attack to bone marrow erythroblasts (98). Moreo-
ver, studies evidence an increased RDW in patients 
with COVID-19, thus suggesting the existence of 
underlying erythroid myelodysplasia, as RDW is 
higher when immature cells are produced (99). It 
has been found that SARS-CoV-2 interacts through 
ACE2, CD147, CD26, and other receptors located on 
erythrocytes and/or blood cell precursors, thus 
causing viral endocytosis. Consequently, the virus 
would attack the heme on the 1-beta chain of hae-
moglobin, inducing haemolysis and forming a 
complex with the released heme, producing a 
quote of dysfunctional haemoglobin (100).
Limitations of the study
A large proportion of the primary research is based 
on Asian patients; therefore, further verification is 
needed in populations in other areas. Eventually, 
further investigations are needed to assess geo-
graphic variability among blood parameters. This 
is a review of the current scientific literature with 
no statistical outcome measures. Therefore, these 
results may not be generalizable to all popula-
tions. Finally, the rapidly evolving nature of COV-
ID-19 and the continuous discovery of novel data 
are additional limitations of this article.
Conclusions
Coronavirus disease 2019 has prominent manifes-
tations from the hematopoietic system. Common 
haematological abnormalities have been identi-
fied in COVID-19 patients. Since the early stage of 
the disease, not only the platelets and lympho-
cytes but also haemoglobin, eosinophils, and ba-
sophils present a marked decrease, associating 
with the disease severity and clinical outcome. At 
the moment, the kinetics of monocytes in COV-
ID-19 infection is still undefined, as SARS-CoV-2 in-
fection of monocytes seems to directly impair the 
anti-viral adaptive immune responses. Finally, an 
increase of neutrophils and the two markers NLR 
and PLR seem to correlate with progressive dis-
ease. Careful evaluation of laboratory indices at 
baseline and during the disease course can assist 
clinicians in formulating a tailored treatment ap-
proach and promptly provide intensive care to 
those who are in greater need.
This review has emphasized the importance of 
laboratory information in the management of 
COVID-19, further studies are worth describing the 
association between the dynamic haematological 
responses and the progression and outcome of 
the disease.
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